Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Atlanta, GA, 30341, United States.
Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, 4770 Buford Hwy NE, Atlanta, GA, 30341, United States.
Clin Biochem. 2023 Jun;116:42-51. doi: 10.1016/j.clinbiochem.2023.03.010. Epub 2023 Mar 20.
Accurate and reliable measurement of human serum free thyroxine (FT4) is critical for the diagnosis and treatment of thyroid diseases. However, concerns have been raised regarding the performance of FT4 measurements in patient care. Centers for Disease Control and Prevention Clinical Standardization Programs (CDC-CSP) address these concerns by creating a FT4 standardization program to standardize FT4 measurements. The study aims to develop a highly accurate and precise candidate Reference Measurement Procedure (cRMP), as one key component of CDC-CSP, for standardization of FT4 measurements.
Serum FT4 was separated from protein-bound thyroxine with equilibrium dialysis (ED) following the recommended conditions in the Clinical and Laboratory Standards Institute C45-A guideline and the published RMP [20,21,23]. FT4 in dialysate was directly quantified with liquid chromatography-tandem mass spectrometry (LC-MS/MS) without derivatization. Gravimetric measurements of specimens and calibrator solutions, calibrator bracketing, isotope dilution, enhanced chromatographic resolution, and T4 specific mass transitions were used to ensure the accuracy, precision, and specificity of the cRMP.
The described cRMP agreed well with the established RMP and two other cRMPs in an interlaboratory comparison study. The mean biases of each method to the overall laboratory mean were within ±2.5%. The intra-day, inter-day, and total imprecision for the cRMP were within 4.4%. The limit of detection was 0.90 pmol/L, which was sufficiently sensitive to determine FT4 for patients with hypothyroidism. The structural analogs of T4 and endogenous components in dialysate did not interfere with the measurements.
Our ED-LC-MS/MS cRMP provides high accuracy, precision, specificity, and sensitivity for FT4 measurement. The cRMP can serve as a higher-order standard for establishing measurement traceability and provide an accuracy base for the standardization of FT4 assays.
准确可靠地测量人血清游离甲状腺素 (FT4) 对于甲状腺疾病的诊断和治疗至关重要。然而,人们对患者护理中 FT4 测量的性能提出了担忧。疾病控制与预防中心临床标准化计划 (CDC-CSP) 通过创建 FT4 标准化计划来解决这些问题,以实现 FT4 测量的标准化。该研究旨在开发一种高度准确和精确的候选参考测量程序 (cRMP),作为 CDC-CSP 的一个关键组成部分,用于 FT4 测量的标准化。
根据临床和实验室标准协会 C45-A 指南和已发表的 RMP [20,21,23]中推荐的条件,用平衡透析 (ED) 将血清 FT4 从结合甲状腺素中分离出来。无需衍生化,直接用液相色谱-串联质谱 (LC-MS/MS) 定量分析透析液中的 FT4。采用重量法测量标本和校准液、校准液内标、同位素稀释、增强色谱分辨率和 T4 特异性质量转移,以确保 cRMP 的准确性、精密度和特异性。
在一项实验室间比较研究中,所描述的 cRMP 与已建立的 RMP 和另外两种 cRMP 吻合良好。每种方法相对于总实验室平均值的平均偏差均在±2.5% 以内。cRMP 的日内、日间和总不精密度均在 4.4% 以内。检测限为 0.90 pmol/L,足以灵敏地测定甲状腺功能减退症患者的 FT4。透析液中的 T4 结构类似物和内源性成分不会干扰测量。
我们的 ED-LC-MS/MS cRMP 为 FT4 测量提供了高度的准确性、精密度、特异性和灵敏度。cRMP 可以作为建立测量溯源性的更高阶标准,并为 FT4 测定的标准化提供准确度基础。